A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients with Diffuse Large B-Cell Lymphoma in the MEA Region

Trial Identifier: D8220R00080
Sponsor: AstraZeneca
Start Date: July 2025
Primary Completion Date: January 2027
Study Completion Date: January 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Egypt, N/A Cairo, N/A, Egypt, N/A
Egypt, NA Alexandria, NA, Egypt, NA
Egypt, NA Cairo, NA, Egypt, NA
Egypt, NA Mansoura, NA, Egypt, NA
Egypt, NA Sohag, NA, Egypt, NA
Egypt, NA Tanta, NA, Egypt, NA
Iraq, NA Baghdad, NA, Iraq, NA
Jordan, NA Amman, NA, Jordan, NA
Kuwait, NA Kuwait City, NA, Kuwait, NA
Morocco, NA Casablanca, NA, Morocco, NA
Morocco, NA Rabat, NA, Morocco, NA
Oman, NA Muscat, NA, Oman, NA
Qatar, NA Doha, NA, Qatar, NA
Saudi Arabia, NA Dammam, NA, Saudi Arabia, NA
Saudi Arabia, NA Jeddah, NA, Saudi Arabia, NA
Saudi Arabia, NA Riyadh, NA, Saudi Arabia, NA
Turkey, NA Ankara, NA, Turkey, NA
Turkey, NA Antalya, NA, Turkey, NA
Turkey, NA Istanbul, NA, Turkey, NA
Turkey, NA Izmir, NA, Turkey, NA
United Arab Emirates, NA Abu Dhabi, NA, United Arab Emirates, NA